Akero Therapeutics, Inc. (NASDAQ:AKRO - Get Free Report) Director G. Walmsley Graham bought 50,000 shares of the firm's stock in a transaction dated Thursday, March 27th. The stock was purchased at an average price of $43.55 per share, with a total value of $2,177,500.00. Following the transaction, the director now owns 1,200,000 shares in the company, valued at approximately $52,260,000. This represents a 4.35 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.
G. Walmsley Graham also recently made the following trade(s):
- On Tuesday, March 25th, G. Walmsley Graham acquired 91,309 shares of Akero Therapeutics stock. The stock was acquired at an average cost of $44.75 per share, with a total value of $4,086,077.75.
- On Thursday, January 30th, G. Walmsley Graham bought 200,000 shares of Akero Therapeutics stock. The shares were acquired at an average cost of $48.00 per share, for a total transaction of $9,600,000.00.
Akero Therapeutics Stock Performance
AKRO stock opened at $43.58 on Friday. Akero Therapeutics, Inc. has a fifty-two week low of $17.86 and a fifty-two week high of $58.40. The company has a market capitalization of $3.47 billion, a P/E ratio of -11.62 and a beta of -0.19. The company has a 50-day simple moving average of $45.66 and a 200 day simple moving average of $34.90. The company has a quick ratio of 17.25, a current ratio of 17.25 and a debt-to-equity ratio of 0.05.
Akero Therapeutics (NASDAQ:AKRO - Get Free Report) last posted its quarterly earnings data on Friday, February 28th. The company reported ($0.99) EPS for the quarter, missing analysts' consensus estimates of ($0.98) by ($0.01). Sell-side analysts predict that Akero Therapeutics, Inc. will post -3.99 earnings per share for the current fiscal year.
Wall Street Analyst Weigh In
A number of equities research analysts recently weighed in on the stock. Canaccord Genuity Group boosted their price objective on shares of Akero Therapeutics from $56.00 to $73.00 and gave the company a "buy" rating in a research report on Tuesday, January 28th. UBS Group raised their price target on Akero Therapeutics from $42.00 to $109.00 and gave the stock a "buy" rating in a report on Friday, January 31st. Morgan Stanley restated an "overweight" rating on shares of Akero Therapeutics in a research report on Sunday, March 2nd. Bank of America raised Akero Therapeutics from a "neutral" rating to a "buy" rating and increased their target price for the stock from $35.00 to $63.00 in a research report on Thursday, January 30th. Finally, HC Wainwright boosted their price target on shares of Akero Therapeutics from $72.00 to $75.00 and gave the company a "buy" rating in a report on Monday, March 3rd. Nine analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has an average rating of "Buy" and a consensus price target of $76.29.
View Our Latest Stock Report on Akero Therapeutics
Institutional Inflows and Outflows
Several large investors have recently bought and sold shares of AKRO. Wellington Management Group LLP lifted its holdings in Akero Therapeutics by 54.4% in the 3rd quarter. Wellington Management Group LLP now owns 7,896,632 shares of the company's stock valued at $226,554,000 after acquiring an additional 2,782,029 shares during the last quarter. Point72 Asset Management L.P. bought a new stake in shares of Akero Therapeutics in the 3rd quarter worth approximately $37,392,000. RTW Investments LP lifted its stake in Akero Therapeutics by 15.9% during the fourth quarter. RTW Investments LP now owns 6,859,823 shares of the company's stock valued at $190,840,000 after purchasing an additional 940,388 shares during the last quarter. Deep Track Capital LP boosted its holdings in Akero Therapeutics by 116.0% during the fourth quarter. Deep Track Capital LP now owns 1,490,000 shares of the company's stock worth $41,452,000 after buying an additional 800,216 shares in the last quarter. Finally, Balyasny Asset Management L.P. acquired a new position in Akero Therapeutics in the fourth quarter worth approximately $18,059,000.
Akero Therapeutics Company Profile
(
Get Free Report)
Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to contact@insidertrades.com.
